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The association between severe malaria and Plasmodium vivax species is contentious. On the Thai-Myanmar border, all
pregnant women are followed systematically with active weekly malaria screening. Over a 27-year period of providing
antenatal care, 48,983 have been prospectively followed until pregnancy outcome (miscarriage or delivery) and 4,298
women have had P. vivax detected at least once. Reported here is the first known P. vivax-associated death amongst
these women. The initial patient presentation was of uncomplicated P. vivax (0.5% parasitaemia) in a term, multigravida
woman who responded rapidly to oral artesunate and mefloquine treatment, clearing her blood stage parasites within
48 hours. The patient appeared well, was ambulatory and due to be discharged but became unwell with acute
respiratory distress syndrome (ARDS) requiring ventilation three days (67 hours) into treatment. Despite induction and
delivery of a stillborn foetus, ventilatory requirements increased and the patient died on day 7. The patient had a low
body mass index. Sensitive detection with nested PCR confirmed only the presence of P. vivax species and concomitant
infections such as tuberculosis and human immunodeficiency virus (HIV) were also ruled out. The contemporaneous
treatment of acute uncomplicated P. vivax and the onset of ARDS on day 3 in this patient implies a possible but
unconfirmed association with death in this patient. Assuming this death was caused by P. vivax, the risk of ARDS-related
maternal mortality in this setting did not differ significantly between Plasmodium falciparum and P. vivax (0.24 per 1,000
(1/4,158) versus 0.23 per 1,000 (1/4,298), contrary to the increased risk of maternal mortality from P. falciparum compared
to P. vivax, 2.89 per 1,000 (12/4,158) versus 0.23 per 1,000 (1/4,298), P = 0.003.
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On the Thai-Myanmar border Plasmodium falciparum [1]
and Plasmodium vivax [2] malaria are associated with ad-
verse outcomes in pregnancy, with P. falciparum species
typically involved in mortality reports [3]. Tests of lung
function in both uncomplicated P. falciparum and P. vivax
malaria have demonstrated a decrease in diffusion capacity
which has been attributed to a reduction in the pulmonary
capillary vascular component of gas transfer [4]. Following
treatment, gas transfer is progressively reduced due to* Correspondence: rose@shoklo-unit.com
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unless otherwise stated.interstitial and alveolar oedema and is more prominent in
P. vivax compared with P. falciparum infection. Seques-
tration of P. vivax in human lung tissue has not yet been
shown, suggesting non-sequestering mechanisms for acute
respiratory distress syndrome (ARDS), such as soluble me-
diators causing endothelial damage, hypoxia and systemic
shock, resulting in diffuse alveolar-capillary damage [5,6].
Reported in this manuscript is a case of ARDS commen-
cing on day 3 into treatment for uncomplicated P. vivax
infection when the patient appeared to be in the recovery
phase of the illness.Case presentation
In this case a 26-year old, gravida 3, parity 2, ethnic Mon
pregnant woman from Myanmar first presented to the
Shoklo Malaria Research Unit (SMRU) antenatal clinicral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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February 2013. This patient was a literate, non-smoker,
with no history of prior medical problems whose prior
obstetric history included one normal vaginal delivery
and the most recent delivery was a caesarean section in
Moulmein (Mawlamyine) for breech presentation. She
was a migrant worker (migrating between Myanmar and
Thailand) and resident for one month at her present ad-
dress. At the first ANC visit, her vital signs and physical
examination were normal except her body weight, which
was low at 34 kg (BMI only 17.1 kg/m2 in late pregnancy).
Her screening tests were negative for malaria, HIV,
syphilis, and hepatitis B; and glucose-6-phosphate de-
hydrogenase status was normal. Her haematocrit (HCT)
was low at 26% and haemoglobin typing confirmed she
had β-thalassaemia trait, so ferrous and folic acid sup-
plements were commenced. At routine weekly ANC
consultations her malaria smear screening was negative
a total of three times. Note in this area of the border
with multidrug-resistant P. falciparum and P. vivax [7],
women are actively and frequently screened by malaria
smear (weekly and 24-hour service) and all positive
cases are treated (regardless of symptoms) as there is no
drug with proven safety and efficacy for prophylaxis
during pregnancy.
At a gestation of 36 weeks and six days, six weeks (day 0)
after booking, the patient complained of a seven-day his-
tory of fever, along with muscle, joint and abdominal pain,
dizziness, palpitations, anorexia, and sleep disturbance.
On examination the body temperature was slightly ele-
vated at 37.7°C, blood pressure 100/65 mmHg, respiratory
rate 26 breaths per minute (similar to six weeks earlier
when it was 24 breaths per minute), pulse rate 90 per mi-
nute and the fetal heart rate was 134 beats per minute.
Malaria smear showed a 0.5% (16,238/uL) P. vivax parasit-
aemia with all stages of the parasite present (Table 1). Her
complete blood count showed a haemoglobin of 8.4 mg/
dL, HCT 26.7%, mean cell volume 60.8 fl, white blood
cells 1.5 × 103/ml with differential counts (×103/ml) of
neutrophils (1.1), lymphocytes (0.3), monocytes (0.1), eo-
sinophils (0) and basophils (0), and platelet count 138 ×
103/μL and C-reactive protein was 51.2 mg/L, consistent
with a diagnosis of acute P. vivax. Microbiological examin-
ation of blood and urine, and scrub typhus IgG serologyTable 1 Parasite clearance with fixed mefloquine-artesunate o
Day
(hour) Trophozoites Schizonts
0 (0) P. vivax 5/1,000 RBC P. vivax 55/500 W
1 (21) P. vivax 4/500 WBC P. vivax 1/500 WB
2 (48) Negative Negative
3 (65) Negative Negative
na: not applicable as calculated for trophozoite only.were negative. Treatment with fixed mefloquine and arte-
sunate (Far-Manguinhos, Brazil) (artesunate/mefloquine
100 mg/220 mg) was started at one tablet once daily for
three days with a good clinical response. This treatment
was used in place of three days of chloroquine, the standard
treatment, as the patient agreed to participate in a clinical
trial [8]. Three supervised anti-malarial treatment doses
were completed by 48 hours. The parasite count reduced
rapidly (Table 1). The fever clearance time was 12 hours
and the clinical symptoms reduced on day 1 with the pa-
tient only complaining of anorexia but less than on the pre-
vious day, and on day 2 anorexia (again less than the
previous day) and new onset dizziness and palpitations.
On day 2, the patient was well and she was due to be dis-
charged the following day. Around midnight on day 2 she
complained of a small amount of haemoptysis and on day
3 at 65 hours there was a significant deterioration in the
clinical condition of the patient. Her vital signs included a
temperature of 36°C, blood pressure 130/80, respiratory
rate of 39 breaths per minute, heart rate of 90 and oxygen
saturation of 40% on room air. Dyspnoea and haemoptysis
were not associated with chest pain and symptoms were
somewhat relieved by the upright position, not recumbent.
This was improved to 92% with facial mask oxygen at a
flow rate of 10 L/minute. Malaria smear was negative with
only P. vivax gametocytes detected (Table 1). A complete
blood count showed a haemoglobin of 7.2 mg/dL, HCT
22.6%, white blood cell count 5.5 × 103/ml with a differen-
tial counts (×103/ml) of: neutrophils (4.4), lymphocytes
(0.8), monocytes (0.3), eosinophils (0) and basophils (0), and
platelet count of 178 × 103/μL. The C-reactive protein was
80.8 mg/L, sodium 131.7 mEq/L, potassium 3.58 mEq/L,
urea nitrogen 10.2 units, creatinine 1.0 mg/dL, total biliru-
bin 1.58 mg/dL, direct bilirubin 0.74 mg/dL, AST 67 U/L,
ALT 22 U/L, alkaline phosphatase 588 u/L, total protein
6.5 g/dL, and anion gap 15.2 mmol/L, all of which were
considered to be consistent with recovering acute malaria.
Intensive care was not available at the field hospital
where the patient had been admitted and the patient was
referred to the district hospital (75 minutes by road) where
she was intubated in the casualty department and admit-
ted to the intensive care unit. Arterial blood gases ob-
tained after intubation with 100% oxygen revealed a pH of
7.32, PaCo2 34 mmHg, a base excess −8.7 mmol/L, andnce daily dosing
Parasite count Parasitaemia/uL
Gametocytes
BC P. vivax 10/500 WBC 16,238
C P. vivax 75/500 WBC 12
P. vivax 3/500 WBC n a
P. vivax 1/500 WBC n a
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cardiogram which showed normal right-sided heart pres-
sures and volumes, and a chest radiograph showed bilateral
pulmonary (fluffy) infiltrates. Two separate sputum tests for
acid fast bacilli were negative. Treatment with artesu-
nate, clindamycin, chloramphenicol, ceftriaxone, and
frusemide was commenced. An induction on the second
day of hospitalization (day 4 since first diagnosis of P.
vivax) for known fetal death in utero resulted in a for-
ceps delivery of a stillborn 2,500 g normal male infant.
Unfortunately, after delivery ventilator pressures con-
tinued to increase [9]. On day 5 her condition worsened
with bilateral pneumothorax. A CT scan with contrast
done after insertion of bilateral chest drains reported
ground glass opacity of the lung tissue and no pleural
effusion. The patient had a cardiac arrest later the same
day and died on day 7. No autopsy was done.
Species PCR
Nested PCR was performed on DNA extracted from 565
uL of packed red blood cells obtained just prior to treat-
ment, following the protocol [10] with the following ex-
ceptions: the QIAamp DNA blood mini kit (Qiagen,
Germany) was used to extract the DNA and Bioline re-
agents (BIOTAQ™ DNA polymerase) were used to set up
20 μl PCR reactions. The sensitivity of the nested PCR
assay at SMRU is 1 parasite/uL of whole blood for P. fal-
ciparum; 1 parasite/uL of whole blood for P. vivax; 10 par-
asites/uL of whole blood for Plasmodium malariae and
6.3 parasites/uL of whole blood for Plasmodium ovale.
Using these methods the sample was found to be positive
only for P. vivax and negative for other Plasmodium spp.
Acute respiratory distress syndrome, malaria
and pregnancy
While sequestration of P. vivax in the lung circulation has
been suggested clinically [4] but not proven [6,11] there
are in vitro conditions where adherence of P. vivax-in-
fected red blood cells (RBC) has been demonstrated
(immobilized chondroitin sulphate A and hyaluronic acid
and fresh placental cells [12]; chondroitin sulphate A and
intracellular adhesion molecule-1 receptors on human
lung endothelial cells, Saimiri brain endothelial cells and
placental cryosections [13]) although to a lesser extent
than observed with P. falciparum. In non-pregnant adults,
P. vivax-associated ARDS typically occurs after parasit-
aemia has declined on day 2 or 3 and a review of pub-
lished case reports indicate that rapid intubation and
ventilation are important for survival and cases that have
survived were not pregnant (91.7% (22/24)) [5,14]. In a
broad review of the clinical spectrum or P. vivax, ARDS as
a single complication has been reported in low numbers
over the last 20 years, mainly from high income, non-
endemic countries with a low case fatality rate. This iscontrary to much higher rates (case fatality rate of 50-
67%) from more recent reports from endemic countries of
severe vivax with ARDS occurring as part of multiple
organ dysfunction/failure [15]. The risk of ARDS in rela-
tion to uncomplicated P. vivax has not been quantified,
while for P. falciparum it has been estimated to be 0.1%
(three in 3,300) US Army soldiers in Vietnam [16].
Systematic malaria screening (and treatment when
positive) of all pregnant women at weekly antenatal con-
sultations was introduced in 1986 at SMRU to reduce P.
falciparum malaria-related maternal mortality [3] which
was estimated at 1% of all pregnant women annually [2].
Since then and until the patient in this case died, there
were 48,983 prospectively followed pregnancies with a
known outcome (birth or miscarriage) and 12 P. falcip-
arum and one P .vivax (the case in point) related maternal
deaths, with each species accounting for one ARDS death.
Amongst this cohort of pregnant women, malaria screen-
ing detected at least one episode of P. falciparum or P.
vivax in 4,158 and 4,298 women, respectively. Assuming
the case in point was caused by P. vivax the comparative
rates of malaria-related mortality were: P. falciparum 2.89
per 1,000 (12/4,158) and P. vivax 0.23 per 1,000 (1/4,298),
P = 0.003; whereas the ARDS-related malaria mortality
was not significantly different for P. falciparum 0.24 per
1,000 (1/4,158) and for P. vivax and 0.23 per 1,000 (1/
4,298) P = 1.000.
Reviews of cases suggest P. vivax-associated ARDS is
mostly reported to occur after the start of anti-malarial
treatment and potentially more cases will be seen with
the spread of chloroquine-resistance and use of alterna-
tive regimens without the same anti-inflammatory drug
properties [15]. However, mefloquine, which was the part-
ner to artesunate in this case, also has anti-inflammatory
properties [17].
Conclusion
The maternal death reported here is highly unusual in the
context of the very high numbers of prospectively followed
pregnancies with a confirmed diagnosis and treatment of
P. vivax in this population. The patient was in late preg-
nancy, symptomatic, moderately anaemic with known
β-thalassaemia trait and with a relatively high P. vivax
parasitaemia. She was treated for uncomplicated malaria
infection, took oral artemisinin-based anti-malarials and
appeared to be recovering well. Unexpectedly ARDS de-
veloped on day 3 after treatment was completed and when
trophozoites were no longer detectable on the peripheral
blood smear. Although ventilated, she died from compli-
cations of ventilation. While no other cause for ARDS was
diagnosed in this patient, she did have a low body weight
and without autopsy an underlying condition cannot
be completely ruled out. While most P. vivax-associated
ARDS cases reported in the literature have recovered, they
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ity may have been related to the original P. vivax infection
but this cannot be proven. If it is assumed that the pa-
tient’s cause of death was caused by P. vivax-associated
ARDS, then the risk of ARDS-related maternal mortality
in this setting was similar for P. falciparum and P. vivax
infection, contrary to malaria-related mortality which was
more than 12-fold higher with P. falciparum.
Consent
Written informed consent was obtained from the patient
for publication before she died as she was enrolled to a
study (http://clinicaltrials.gov/ct2/show/NCT01054248) ap-
proved by the Oxford Tropical Research Ethics Committee
(reference 45–09) and the Faculty of Tropical Medicine,
Mahidol University, Thailand (reference MUTM 2009-065-
01). A copy of the written consent is available for review by
the Editor-in-Chief of this journal.
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